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Transcranial direct current stimulation (tDCS) and melatonin can effectively treat pain.
Given their potentially complementary mechanisms of action, their combination could
have a synergistic effect. Thus, we tested the hypothesis that compared to the control
condition and melatonin alone, tDCS combined with melatonin would have a greater
effect on pain modulatory effect, as assessed by quantitative sensory testing (QST)
and by the pain level during the Conditioned Pain Modulation (CPM)-task. Furthermore,
the combined treatment would have a greater cortical excitability effect as indicated
by the transcranial magnetic stimulation (TMS) and on the serum BDNF level. Healthy
males (n = 20), (aged 18–40 years), in a blinded, placebo-controlled, crossover,
clinical trial, were randomized into three groups: sublingual melatonin (0.25 mg/kg) +
a-tDCS, melatonin (0.25 mg/kg) + sham-(s)-tDCS, or sublingual placebo+sham-(s)-
tDCS. Anodal stimulation (2 mA, 20 min) was applied over the primary motor cortex.
There was a significant difference in the heat pain threshold (◦C) for melatonin+a-tDCS
vs. placebo+s-tDCS (mean difference: 4.86, 95% confidence interval [CI]: 0.9 to 8.63)
and melatonin+s-tDCS vs. placebo+s-tDCS (mean: 5.16, 95% CI: 0.84 to 8.36). There
was no difference between melatonin+s-tDCS and melatonin+a-tDCS (mean difference:
0.29, 95% CI: −3.72 to 4.23). The mean change from the baseline on amplitude
of motor evocate potential (MEP) was significantly higher in the melatonin+a-tDCS
(−19.96% ± 5.2) compared with melatonin+s-tDCS group (−1.36% ± 5.35) and with
placebo+s-tDCS group (3.61% ± 10.48), respectively (p < 0.05 for both comparisons).
While melatonin alone or combined with a-tDCS did not significantly affect CPM task
result, and serum BDNF level. The melatonin effectively reduced pain; however, its
association with a-tDCS did not present an additional modulatory effect on acute
induced pain.
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Trial registration: current controlled trial is registered at clinical
trials.gov upon under number: NCT02195271.
Introduction
Transcranial direct current stimulation (tDCS) is capable of
modulating pain systems. Several studies have shown that tDCS
applied on the primary motor cortex (M1) and/or the prefrontal
cortex (among others) shows clinically significant pain reduction
in various chronic pain syndromes, such as fibromyalgia (Fregni
et al., 2006; Lefaucheur et al., 2008; Valle et al., 2009; Mendonca
et al., 2011; Mylius et al., 2012; O’Connell et al., 2014; Vaseghi
et al., 2014), Phantom pain (Bolognini et al., 2013), trigeminal
neuralgia (Hagenacker et al., 2014), chronic migraine (Dasilva
et al., 2012), low back pain (O’Connell et al., 2013) and
Myofascial Pain Syndrome (Sakrajai et al., 2014) tDCS was
shown to have a benefit on decreasing pain scores. However,
these positive results should not be considered in isolation as
some of these studies have methodological shortcomings that
may bias these results, leading for instance to false positive
findings. The proposed mechanism for tDCS on pain rests on
its polarity-dependent shifts of the resting membrane potential
and consequent cortical and subcortical modulation (Simis et al.,
2014). Hence, one strategy to optimize the analgesic effects
of active (a)-tDCS is its combination with pharmacological
interventions (Brunoni et al., 2011c).
Which has shown advantages such as the augmentation of its
clinical effects, as was observed when combined with sertraline
for major depression (Brunoni et al., 2013). In pain, a case report
of tDCS combined with D-cycloserine (anN-methyl-D-aspartate
agonist) suggested its beneficial clinical effects (Antal and Paulus,
2011).
Pre-clinical evidence have demonstrated melatonin effects
on inflammatory (Laste et al., 2013) and neuropathic pain
(Ambriz-Tututi and Granados-Soto, 2007), and clinical trials
in acute (Caumo et al., 2007, 2009) and chronic human
pain (Citera et al., 2000; Hussain et al., 2011; Schwertner
et al., 2013; Vidor et al., 2014). Melatonin modulates pain
systems such as the gamma-aminobutyric acid (GABAergic) and
opioidergic systems (Ambriz-Tututi and Granados-Soto, 2007;
Zurowski et al., 2012). Its long-term use in endometriosis and
fibromyalgia improves pain and decreases the levels of serum
brain-derived neurotrophic factor (BDNF; Schwertner et al.,
2013; de Zanette et al., 2014). Furthermore, an experimental
study showed that melatonin constrained the synaptic plasticity
in a concentration-dependent manner (≥1 nM) (Wang et al.,
2005), affecting networks that are not directly influenced by
tDCS, such as subcortical pain circuits. The concurrent use
of tDCS and conditioned pain modulation (CPM), which
modulates the descending pain control systems, also show a
synergistic effect (Reidler et al., 2012); thus, it is conceivable
that such a combination would potentiate melatonin’s effects
on pain.
Plasticity in both excitatory and inhibitory circuits in the
human motor cortex is regulated by homeostatic metaplasticity
(Murakami et al., 2012). Therefore, in this explanatory trial, we
tested the hypothesis that compared to the control condition
and melatonin alone, a-tDCS combined with melatonin would
have a greater effect on pain modulatory effect, as assessed
by quantitative sensory testing (QST) and by the pain level
during the CPM-task. Furthermore, the combined treatment
would have a greater cortical excitability effect as indicated by
the transcranial magnetic stimulation (TMS) and on the serum
BDNF level.
Material and Methods
Study Design, Setting, and Participants
All volunteers provided written informed consent before
participating in this study, and the protocol was approved by
the Research Ethics Committee at the Hospital de Clínicas
de Porto Alegre (Institutional Review Board IRB -13-0155)
according to the Declaration of Helsinki. The volunteers were
recruited from the general population by advertisement postings
in the universities, on the internet, and in public places in
the Porto Alegre area. Subjects were considered eligible to
participate if they were male, right-handed, and between 19
and 40 years of age, and were screened for eligibility by phone.
They answered a structured questionnaire that assessed the
following variables: current acute or chronic pain conditions,
use of analgesics in the past week, rheumatologic disease,
clinically significant or unstable medical or psychiatric disorder,
history of alcohol or substance abuse in the past 6 months,
neuropsychiatric comorbidity, and use of psychotropic drugs.
Subjects responding affirmatively to any of these questions,
and those with contra-indications for TMS (Rossi et al., 2009)
were excluded. Subjects with Beck Depression Inventory (BDI;
Warmenhoven et al., 2012) scores higher than 13 were also
excluded (Beck et al., 1996). We include males only to exclude
the influence of the cyclical fluctuation of gonadal steroids
during the menstrual cycle on pain threshold and in the
cortical excitability parameters (Smith et al., 2002; Stefani et al.,
2012).
Sample Size
The number of subjects in each study group was determined
according to parameters of a previous study (Stefani et al., 2012).
A priori estimate indicated that in a superiority test from a cross-
over design, a sample size of 20 subjects divided into three groups
with a 2:2:1 ratio, in three sessions, to test for difference between
interventions groups onmean of 2.5◦C (SD 3◦C) for the heat pain
threshold (HPT), with a variation coefficient of 0.5, superiority
margin 0.22 and to achieves 80% power at a 5% significance.
We estimated a sample size for a large effect size using the
Analysis of variance. To be an incomplete blocks crossover trial
each subject received some interventions but not all subjects
received interventions in the third session. This mean that the
allocation in a cross-over manner in the first and second sessions
was a-tDCS+melatonin (n = 8), s-tDCS+melatonin (n = 8) and
in s-tDCS+placebo (n = 4), respectively. In the third session
a-tDCS+melatonin (n = 4), s-tDCS+melatonin (n = 4) and
in s-tDCS+placebo (n = 2), respectively. The estimative was
determined using the Power Analysis and Sample Size Software
PASS version 13 (NCSS Statistical Software, Kaysville, Utah).
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Interventions
The intervention involved one dose of sublingual melatonin
(Sigma Chemical, Germany; batch-by-batch certificates of
analysis for authenticating the purity of each batch provided):
0.25 mg/kg (maximum dose 20 mg), or placebo (Stefani et al.,
2013). This solution was combined with 0.5 mL of 10%
glucose solution. The placebo was an equivalent volume of
10% glucose solution. The tDCS was introduced 10 min after
administer the melatonin to conclude the session (20 min)
30 min after administer the melatonin, since in previous
study we demonstrated that at this time we get a serum
peak of melatonin when it is used sublingual (Stefani et al.,
2013).
tDCS is a therapeutic tool that is relatively inexpensive,
non-invasive, painless, safe, its shape can be simulated (sham)
and used efficiently for double-blinded studies. In this study,
the anode was positioned over the left M1, and the cathode
was positioned on the right supraorbital region. The rubber
electrodes were inserted into a 35-cm2 sponge (moistened with
NaCl). The current was 2 mA, and the attachment of electrodes
to the scalp was maintained by an elastic band (Vandermeeren
et al., 2010). The stimulation time was 20 min, consistent with
previous studies (Valle et al., 2009; Knotkova et al., 2013). For the
sham conditions, the device was turned off after 1 min of starting
the stimulation, which is a reliable blinding method (Brunoni
et al., 2011b), capable of mimicking the common adverse
effects induced by the real stimulation (Brunoni et al., 2011a).
The evaluators and subjects were blinded to the treatment;
contact between participants was avoided to enhance study
blinding.
Randomization
The randomization was generated by a computer with a fixed
block size of 5. Twenthy subjects were randomly allocated to
receive three sequences of treatment (melatonin+active(a)-tDCS,
melatonin+sham(s)-tDCS, and s-tDCS+placebo). An allocation
of 2:2:1 in favor of the melatonin treatment to maximize
allocation to the experimental group and to improve the
experimental power. To be an incomplete blocks crossover trial
each subject received some interventions but not all subjects
received interventions in the third session. This mean that
the allocation in a cross-over manner in the first and second
sessions was a-tDCS+melatonin (n = 8), s-tDCS+melatonin
(n = 8) and in s-tDCS+placebo (n = 4), respectively. In the third
session a-tDCS+melatonin (n = 4), s-tDCS+melatonin (n = 4)
and in s-tDCS+placebo (n = 2), respectively. The experimental
desing and interventions in each session is presented in the
Figure 1. Before the recruitment phase, opaque envelopes
containing the protocol materials were prepared. Each opaque
envelope was sealed and numbered sequentially. The opaque
envelopes were opened by the nurse who administered the
medications only after gaining subjects’ informed and signed
consent.
Blinding
To control for possible measurement bias participants were
instructed to discuss all aspects related to their tDCS treatment
only with their treating physician (rather than the research
personnel). During the sham stimulation, subjects underwent
tDCS experiences that were comparable to the active stimulation.
Individuals other than those responsible for administering the
interventions were blinded to the allocated interventions.
Further, to assess whether blinding was effective, at the end of
the experiment we asked participants to guess whether they had
received active or sham tDCS and to rate their confidence on the
answer on a Likert scale with five categories (no confidence to
completely confident). This scale was used to assess the blinding
about both interventions (tDCS and sublingual).
Outcomes
The primary outcome was the HPT as assessed by QST.
The secondary outcomes were the excitability of the cortical
spinal system indexed by motor-evoked potentials (MEPs), pain
reduction on the Numerical Pain Scale (NPS0−10) during the
CPM task, and other cortical excitability parameters (intra-
cortical facilitation (ICF), current silent period (CSP), intra-
cortical inhibition (ICI)), and serum BDNF.
The method of limits with a computer Peltier-based device
thermode (30 × 30 mm) was used to assess the heat pain
threshold (HPT; Schestatsky et al., 2011). The thermode was
attached to the skin on the ventral aspect of the mid-forearm,
and the temperature was increased at a rate of 1◦C/s, from 32◦C
to amaximum of 52◦C, which primarily stimulates C-nociceptive
afferents (Backonja et al., 2013). Participants were asked to
press a button as soon as the sensation of heat began (heat
detection threshold) and as soon as the stimulation became
painful (HPT). Three assessments were performed with an inter-
stimuli interval of 40 s. Each subject’s HPT was defined as the
mean painful temperature of the three assessments. The position
of the thermode was slightly altered between trials (although it
remained on the left ventral forearm) to avoid either sensitization
or response suppression of the cutaneous heat nociceptors. The
same equipment was used to determine the maximum tolerated
temperature, where volunteers pressed a button to stop the
temperature increase. If 52◦Cwas achieved before reporting pain,
the device cooled down automatically and the pain threshold was
considered unknown.
To test the CPM, we used the term CPM rather than
diffuse noxious inhibitory control/DNIC because of the recent
recommendations of Yarnitsky et al. (2010), we used the protocol
of Tousignant-Laflamme et al. (2008) and the guidelines for
the cold-pressor task (CPM-TASK) as an experimental pain
stimulus (von Baeyer et al., 2005). The CPM-TASK activates the
diffuse noxious inhibitory control-like effect (CPM) because it
is a strong nociceptive stimulus that takes place over a lengthy
time span (Willer et al., 1989) and is applied over a large body
surface area (Marchand and Arsenault, 2002). The CPM-TASK
allows us to modify the endogenous pain-modulating system.
To quantify the CPM, we evaluated the pain intensity of three
tonic heat pain (HPT) test stimuli separated by a CPM-TASK.
Although the HPT might lead to habituation and sensitization
according to the dual process theory, cold water to zero is a
reliable stimulus to induce CPM (Tousignant-Laflamme et al.,
2008).
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FIGURE 1 | Experimental desing—Cross-over, assessements and
interventions in each one of three sessions. The period between each
session was 1 week. (Motor evoked potential: MEP); Intra-cortical inhibition (ICI)
expresses the relationship between the amplitude of wave and motor evoked
potentials (relative amplitude, express in %), at inter-stimuli intervals (ISIs) of 2
ms with paired-pulse. The first is a sub-threshold stimulus [80% of the rest
motor threshold (rMT)] followed by the second one which is a suprathreshold
stimulus (130% rMT). Cortical silent period (CSP) expressed in milliseconds
(ms); Motor-evoked potentials (MEP) expressed in mV, evoked by a stimulus of
130% the intensity of the rMT, and should have peak-to-peak MEP amplitude of
at least 1 mV. Conditioned Pain Modulation (CPM); Visual Analogue Sleepiness
Scale (VASS); Brain Deriavete Neural Factor (BDNF).
CPM-Task: The cold-pressor task was used as a conditioning
stimulus to elicit a strong and prolonged pain sensation to trigger
the CPM. The CPM-TASK consisted of immersing the non-
dominant hand in cold water (zero to 1◦C) for 1 min. During
the last 30 s of the cold-water immersion, the HPT procedure
was administered over the right forearm (dominant forearm).
The temperature was held constant during the experiment for
each subject. The HPT that elicited pain ratings of 6/10 on the
Numerical Pain Scale [(NPS) 0/10] (HPT60) was used for the
first HPT before the CPM-TASK (HPT0). After a short break,
the HPT0 was applied at the volar region. Following HPT0,
the CPM-TASK was used to trigger the CPM. One minute
after the CPM-TASK, we applied the second HPT (HPT1).
We quantified the amount of the CPM by subtracting the
mean pain rating of HPT1 from the first HPT0 before the
CPM-TASK (HPT1); negative values indicate inhibitory CPM.
This test was applied after measuring the cortical excitability
parameters.
Cortical excitability parameters were registered through
surface electromyography recordings, which were gathered at
the contralateral right first dorsal interosseous muscle using
Ag/AgCl electrodes. First, the resting motor threshold (RMT)
was determined by obtaining five MEPs with a peak-to-peak
amplitude of 50 µV out of 10 consecutive trials using the
minimum output of the TMS device. Next, 10 MEPs were
recorded with an intensity of 130% of the individual RMT.
The CSPs were assessed during muscle activity measured by
a dynamometer to be approximately 20% of the maximal
force. Accordingly, 10 CSPs were recorded using an intensity
of 130% of the RMT. The short-interval ICI (SICI), using
an inter-stimulus interval of 2 ms was also assessed. The
first conditioning stimulus was set at 80% of the RMT,
whereas the second test stimulus was set at 100% of the
individual MEP intensity. The ICF was assessed with an inter-
stimulus interval of 12 ms. Paired-pulse TMS was conducted
in a randomized order for a total of 30 trials (10 for each
SICI, ICF, and control stimuli). Off-line analyses included
collecting the amplitudes of all MEP, SICI, and ICF values,
as well as the duration of the CSPs. The corresponding
units for these parameters are mV for MEP, ratio to MEP
for SICI and ICF, and ms for CSP (Pascual-Leone et al.,
1994).
The serum BDNF concentration was determined using an
enzyme-linked immunosorbent assay kit (Chemicon/Millipore,
catalog n◦ CYT306). The serum was frozen at −80◦C until the
assays were performed.
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Other Instruments and Assessments
Pain catastrophizing thinking was assessed using the
validated Brazilian-Pain Catastrophizing Scale (Sehn et al.,
2012). Depression symptoms were screened using the BDI
(Warmenhoven et al., 2012). Anxiety was measured with the
State-Trait Anxiety Inventory (STAI), adapted to Brazilian
Portuguese (Kaipper et al., 2010). Demographic data were
gathered using a standardized questionnaire. The clinical
assessment of sedation was determined by simultaneous
recording using a visual analog scale (VAS0–10) ranging from
zero (sleepiness) to 10 (completely awake). To assess safety,
we used the Systematic Assessment for Treatment with tDCS
questionnaire based on previously reported adverse events
(Brunoni et al., 2011b).
Statistical Analyses
The differences among the sequence cohort were examined with
the analysis of variance (ANOVA) for parametric variables,
and categorical outcomes were examined by chi-square or
Fisher’s tests.
Continuous data were evaluated for normality using Shapiro-
Wilk test. After verifying the corresponding assumptions the
results were evaluated using the absolute mean variation for
HPT of delta values (post-treatment minus pre-treatment). We
analyzed the data using a mixed ANOVA model in which
the independent variables were the cohort time of session
(time), treatment (placebo+s-tDCS, melatonin+s-tDCS, and
melatonin+a-tDCS), the interaction term time vs. the treatment
group, and subject identification.
The results were evaluated using the absolute mean variation
for MEPs of the percentage of variation [(post-treatment−pre-
treatment)/post-treatment] × 100. The HPT was adjusted by
the sleepiness score assessed by a VAS0–10. All analyses were
performed with two-tailed tests at the 5% significance level.
All analyses were adjusted for multiple comparisons using
Bonferroni test. However due to the excessive number of
outcomes, some of our results should be considered exploratory
and thus need to be replicated in confirmatory trials. An
intention-to-treat analys was planned according to the last
observation carried forward through the time points if we had
oberved dropouts. The analyses were performed with SPSS
version 20.0 (SPSS, Chicago, IL).
Results
Subject Characteristics
Twenty healthy subjects were randomized, with the ratio
of 2:2:1 to the three interventions, in three sessions to
participate in the three sequences of treatment (Figure 1). The
demographic and psychological characteristics of the subjects
according to the sequence allocation were comparable and
are shown in Table 1. All subjects completed the course
protocol for which they had been randomized. There was
no carry over effect, tested by comparison of pre-treatment
assessments (p > 0.05). Although participants correctly guessed
the intervention used in the transcranial stimulation (tDCS)
and sublingual, when the question was about the level of
certain of their assigned intervention group, only melatonin
was guessed correctly but tDCS not. A maximum of 23%
of the subjects in each group correctly guessed the active-
tDCS condition; the level of confidence in the intervention was
moderate to high in more than 75% of the individuals in all
groups, and the percentages of answers between groups, for
each item were similar without statistically significant differences
(p > 0.05, for both measures). Importantly, our results would
not change if we exclude subjects with higher incidence of
adverse effects.
The incidence of reported side effects presented a similar
distribution between groups. Headache, neck and scalp pain, skin
redness, mood changes, and difficulties in concentration were
reported by<15% of subjects. Burning and itching were reported
bymore than 25% of the subjects. Tingling was themost common
side effect reported, with an incidence higher than 30%. The
scores on the VAS0–10 (higher score less sleepiness) showed that
placebo+s-tDCS groups 9.62 ± 0.52 induced lower sleepiness
than the active arms (melatonin+a-tDCS 5.62 ± 1.31 and
melatonin+s-tDCS 5.93 ± 1.43; p < 0.01 for each comparison
vs. placebo+s-tDCS), although there was no difference between
the two active tDCS groups (p = 0.9). The VAS0–10 scores
for sleepiness vs. group comparison did not demonstrate a
significant interaction (F(2,46) = 0.18; p = 0.84). Additionally,
there was no statistically significant effect of sleepiness score on
HPT (β = 0.31, t = 1.16; 95% confidence interval [CI]: −0.23 to
0.85; p = 0.25).
Treatment Effects on the HPT (Primary Outcome)
and on the Descending Modulatory System
(Secondary Outcome)
In the incomplete factorial analysis, there were two factors: (a-
tDCS and s-tDCS) and melatonin (real or placebo). The analysis
showed no significant interaction between tDCS and melatonin
on HPT (F(2,46) = 0.3; p = 0.95), but a significant main effect for
treatment was observed (F = (2,46) = 3.94; p = 0.02); (Table 2). The
differences mean in the HPT tests are presented in (Figure 2).
The function of the descending modulatory system was
assessed using the CPM task. Although all the interventions
improved the pain reduction during the CPM task, there were
no differences in their effectiveness between them (p > 0.05).
The reduction in pain scores on the NPS0-10 during the CPM
task was 48.41% (HPT0 = 5.04 ± 1.06; HPT1 = 2.60 ± 1.27)
in the melatonin+active-tDCS group, 37.88% (HPT0 = 4.25 ±
1.37; HPT1 = 2.64 ± 1.55) in the melatonin+sham-tDCS group,
and 33.74% (HPT0 = 4.83 ± 1.06; HPT1 = 3.2 ± 1.42) in
the placebo+sham-tDCS group. These results reveal that the
interventions did not change the descending modulatory system
as assessed by the CPM task.
Effect on the Neurophysiological Outcomes
(Secondary), as Indicated by the TMS Cortical
Excitability Parameters: MEPs, ICI, ICF, CSP, and
BDNF
Similar analyses showed significant main effects of the
intervention group forMEPs (F(2,46) = 11.55; p = 0.03). There was
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TABLE 1 | Values are given as the mean (±SD) or as a frequency according to the sequence cohort (n = 20).
Sequence trails
First (n = 20) Second (n = 20) Third (n = 10) p
Age (years) 25.37 (5.39) 25.67 (5.39) 25.60 (5.27) 0.96
Education (years) 16.33 (4.68) 16.56 (4.67) 16.56 (4.65) 0.85
Smoking (yes/no) 1 (yes: 5.26%) 1 (yes: 5.55%) 1 (yes: 5.26%) 0.52
Social alcohol consumption – not more than once a week
(yes/no)
8 (yes: 42.05%) 8 (yes: 44.44%) 4 (yes: 43.44%) 0.54
Body mass index 25.38 (3.89) 25.78 (3.24) 25.48 (3.22) 0.33
State-anxiety 19.84 (4.02) 19.89 (3.55) 19.87 (3.87) 0.57
Trait-anxiety 15.92 (3.46) 16.17 (3.91) 15.98 (3.22) 0.94
Depressive symptoms on the Beck Inventory 3.79 (3.38) 2.94 (3.10) 3.02 (3.45) 0.73
Pain Catastrophizing Scale–total score 5.84 (6.82) 7.67 (9.15) 6.44 (7.78) 0.35
Brain-derived neurotrophic factor (ng/ml) before intervention
Placebo+s-tDCS 48.78 (15.04) 46.38 (7.89) 47.58 (10.78) 0.52
Melatonin+s-tDCS 50.69 (16.02) 43.9 (11.95) 46.87 (13.04) 0.89
Melatonin+a-tDCS 50.0 (15.02) 45.21 (11.71) 46.34 (13.04) 0.78
Psychophysical pain testing
Heat pain threshold (HPT) (◦C) 42.98 (4.07) 42.7 (3.93) 43.0 (2.77) 0.98
Heat pain threshold 60% (HPT60) (◦C) 44.48 (3.19) 45.02 (3.20) 44.75 (1.98) 0.51
Maximal tolerated heat (◦C) 44.38 (3.26) 44.97 (3.24) 44.75 (1.89) 0.82
SD = standard deviation, tDCS = transcranial direct current stimulation.
TABLE 2 | The mean delta score (SD) (post-treatment values minus pre-treatment values) of the heat pain thresholds and motor-evoked
potentials (n = 20).
Pre- Post- Mean difference % (SD)*
intervention intervention (post-intervention–pre-
intervention, 95% CI)
Heat Pain Threshold (◦C) (primary)
Placebo+s-tDCS 43.0 (2.77) 42.46 (2.97) −0.53 (−1.83 to 0.77) −1.21 (3.52)a
Melatonin+s-tDCS 42.67 (3.39) 44.34 (3.94) 1.67 (0.7 to 2.64) 3.94 (4.81)b
Melatonin+a-tDCS 43.0 (3.90) 43.84 (4.28) 1.50 (0.57 to 2.45) 3.65 (5.54)b
p valueU 0.02
Motor-evoked potential (mV) (secondary)
Placebo+s-tDCS 1.39 (0.19) 1.45 (0.22) 0.06 (−0.36 to 0.22) 4.31 (10.56)a
Melatonin+s-tDCS 1.76 (0.28) 1.73 (0.43) −0.03 (−0.16 to 0.02) −1.36 (5.35)a
Melatonin+a-tDCS 1.84 (0.4) 1.17 (0.5) −0.37 (−0.22 to −0.39) −19.96 (5.2)b
p valueU 0.003
SD = standard deviation, CI = confidence interval, tDCS = transcranial direct current stimulation.
*Percentage represents the percent change, calculated as [(post-intervention–pre-intervention)/post-intervention] × 100.
Up value represents the results from the mixed-model analysis of variance × group interaction (for the main analysis) and for the factorial analysis.
Different superscripts (a and b) indicate significant differences among intervenios groups according to the Bonferroni test.
significant difference in MEP amplitude between the treatment
group melatonin+a-tDCS and the melatonin+s-tDCS group
(−19.96% ± 5.2 vs. −1.36% ± 5.35; mean difference: −18.60%,
95% CI: −42.44 to −7.12; p = 0.03) and melatonin+a-tDCS and
the placebo+s-tDCS group (−19.96% ± 5.2 vs. 3.61% ± 10.48;
mean difference: −23.57%, 95% CI: −39.68 to −1.2; p = 0.01).
However, there was no significant difference in MEP amplitude
between the melatonin+s-tDCS and the placebo+s-tDCS group
(−1.36% ± 5.35 vs. 4.31% ± 10.56; mean difference: −5.67%,
95% CI: −39.68 to −1.2; p = 0.48). The differences between the
groups in the percentage of variation before and after treatment
are shown in Figure 3.
The MEP differences (mean ± SD) before and after
treatment, irrespective of the session sequence, are presented in
Table 2. Melatonin alone did not result in any significant MEP
changes.
The effects of the interventions on the secondary
outcomes related to cortical excitability are presented
in Table 3. The interventions did not induce significant
changes on the other cortical excitability parameters (ICF,
ICI, and CSP). No significant difference between the
treatment groups was observed for the serum BDNF levels
at baseline, which had great variability (Table 1). From
the baseline level, the serum BDNF level demonstrated a
mean decrease of 10.96% in the placebo+s-tDCS group,
whereas the melatonin+s-tDCS and melatonin+a-tDCS groups
presented mean reductions of 12.79% and 6.09%, respectively
(Table 3).
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TABLE 3 | Outcomes related to cortical excitability and serum BDNF (20 subjects) and the number of assessment.
Intervention Mean (SD) p SDM
Dependent variable: resting motor-threshold
Placebo+sham-tDCS (n = 10) 41.10 (5.70) vs. 40.07 (5.83)a 0.69 0.18
Melatonin+sham-tDCS (n = 20) 41.56 (6.54) vs. 42.56 (5.65) a 0.15
Melatonin+active-tDCS (n = 20) 39.11 (6.72) vs. 40.05 (6.20) a 0.13
Dependent variable: cortical silent period
Placebo+sham-tDCS (n = 10) 64.16 (9.8) vs. 63.95 (10.76) a 0.93 −0.02
Melatonin+sham-tDCS (n = 20) 64.51 (20.13) vs. 65.65 (20) a −0.06
Melatonin+active-tDCS (n = 20) 62.08 (21.25) vs. 63.02 (23.38) a −0.05
Dependent variable: intra-cortical facilitation
Placebo+sham-tDCS (n = 10) 1.07 (0.20) vs. 0.99 (0.20) a 0.72 0.4
Melatonin+sham-tDCS (n = 20) 1.03 (0.17) vs. 1.07 (0.20) a −0.24
Melatonin+active-tDCS (n = 20) 1.08 (0.33) vs. 1.05 (0.24) a 0.09
Dependent variable: intra-cortical inhibition
Placebo+sham-tDCS (n = 10) 0.22 (0.19) vs. 0.21 (0.09) a 0.32 0.05
Melatonin+sham-tDCS (n = 20) 0.26 (0.15) vs. 0.29 (0.12) a −0.2
Melatonin+active-tDCS (n = 20) 0.23 (0.10) vs. 0.25 (0.11) a −0.2
Dependent variable: serum BDNF ng/ml
Placebo+sham-tDCS (n = 10) 46.76(13.02) vs. 44.25 (12.66) a 0.48 0.19
Melatonin+sham-tDCS (n = 20) 49.19 (14.42) vs. 45.22(11.18) a 0.27
Melatonin+active-tDCS (n = 20) 48.82 (14.08) vs. 46.19 (12.53) a 0.18
Mean (SD) pre vs. post-intervention.
SD = standard deviation, tDCS = transcranial direct current stimulation.
Standardized mean difference (SMD) [(pre minus post)/baseline standard deviation]. The size effect was interpreted as follows: small, 0.20; moderate, 0.50–0.60 and
large, 0.80.
All comparisons between the melatonin+tDCS, melatonin+sham-tDCS, and placebo+sham-tDCS groups were performed using a mixed analysis of variance model
(p > 0.05 for all comparisons). Different superscripts a indicate absence of significant differences among treatment groups according to the Bonferroni test.
FIGURE 2 | Heat pain threshold scores before and after intervention
presented as delta values (post- minus pre-treatment). Error bars
indicate the standard error of the mean. The letter b indicates a significant
difference between the melatonin+a-tDCS group and the melatonin+s-tDCS
and placebo+s-tDCS groups (p < 0.02). All comparisons were performed
using a mixed analysis of variance model, followed by the Bonferroni
correction for multiple post hoc comparisons. tDCS = transcranial direct
current stimulation.
Discussion
The main findings of this study confirm that melatonin
significantly affects the pain pathways, which are not changed by
the concurrent tDCS stimulation. Furthermore, this effect does
FIGURE 3 | Motor-evoked potential (MEP) changes from baseline
presented as percentages (post intervention minus pre-intervention). A
letter b indicates a significant difference between the melatonin+a-tDCS group
and the melatonin+s-tDCS and placebo+s-tDCS groups (p < 0.05). All
comparisons were performed using a mixed analysis of variance model,
followed by the Bonferroni correction for multiple post hoc comparisons. tDCS
= transcranial direct current stimulation.
not seem to be associated with changes in cortical excitability.
This finding contrasts to our initial hypothesis that melatonin
combined with tDCS would improve pain control, considering
that treatment with tDCS (Valle et al., 2009; Mendonca et al.,
2011) or melatonin alone demonstrated an effect on pain in pre-
clinical (Laste et al., 2012a,b), experimental (Stefani et al., 2013),
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and clinical studies (Caumo et al., 2002, 2007, 2009; Schwertner
et al., 2013; Vidor et al., 2013, 2014) One possible explanation
for this result is that melatonin induced maximum homeostatic
control to modulate the painful stimuli via neurobiological
systems that are common targets for both interventions (i.e.,
melatonin induced a ceiling effect on pain). This hypothesis is
biologically plausible and is supported by pre-clinical evidence
indicating that the GABAergic (Wilhelmsen et al., 2011), opioid,
and glutamatergic systems (Mantovani et al., 2006) act as targets
for both melatonin and tDCS.
Another explanation for the lack of an effect when tDCS
was combined with melatonin may be that melatonin blocked
the effects of tDCS. It has been shown that pharmacological
agents (Liebetanz et al., 2002) such as benzodiazepines, are
capable of partially blocking the clinical effects of tDCS (Brunoni
et al., 2013). Thus, the increased excitability of GABA-A and
GABA-B circuits in M1 might increase the inhibitory tone,
which is responsible for the general occlusion of the subsequent
induction of long-term potentiation- and long-term depression-
like plasticity (Castro-Alamancos and Borrell, 1995; Castro-
Alamancos et al., 1995; Hess et al., 1996). Therefore, it is
plausible that the failure of additive effect of a-tDCS+melatonin
is explained by a similar response, because of melatonin action
on GABA-A receptor (Coloma and Niles, 1988; Niles and Peace,
1990). It is also possible that the lack of interaction effect is a
result of metaplasticity, i.e., when two plasticity protocols are
used together, the effect of the first one modulates that of the
second (Murakami et al., 2012). Other mechanism to explain
this finding is the depotentiation, which refers to two protocols
that when used alone do not induce changes in the excitability,
but when used together cancel out the effect of a preceding
potentiation protocol to achieve homeostasis (Froc et al., 2000;
Yashiro and Philpot, 2008; Müller-Dahlhaus and Ziemann,
2014). Accordingly, the tonic depression of the nociceptive
threshold may result from the activation of pro-nociceptive areas
of the brain or from inhibition of the endogenous pain inhibitory
system (Burkey et al., 1999).
Other explanations for these results, that challenge our
hypothesis, are evidences of previous clinical studies, which
demonstrated that the behavioral data did not indicate
a pain-reducing effect of anodal stimulation (Grundmann
et al., 2011; Jürgens et al., 2012; Luedtke et al., 2012).
Interestingly, previous studies on experimental pain using the
same stimulation paradigm also showed inconclusive effects of
tDCS on psychophysical variables (Grundmann et al., 2011;
Jürgens et al., 2012; Luedtke et al., 2012). These inconclusive
effect of change on cortical nociceptive processing, as a response
to heat pain was also reported in other recent study, which did
not found neither cathodal nor anodal tDCS effect over the left
M1 (1 mA, 15 min) (Ihle et al., 2014).
The effect of a-tDCS on neurophysiological outcomes (such
as evoked potentials) demonstrated in the present study, were
also reproduced in the majority of trials after tDCS (Matsunaga
et al., 2004; Csifcsak et al., 2009; Luedtke et al., 2012). Perhaps
the psychophysical variables depend on a range of different
pathways because evaluation of pain is a more complex process
than mere somatosensory processing in evoked potentials.
Higher stimulation intensities, longer stimulation duration, or
repeated stimulation sessions may be required to produce a
statistically significant experimental pain reduction that matches
the effect observed in chronic clinical pain studies. Although
M1 excitability is a reliable marker for indexing the effects of
interventions on pain (Volz et al., 2013; Dall’Agnol et al., 2014;
Vidor et al., 2014), this marker seems to be more specific for
chronic pain than for acute experimental pain. It also suggests
that melatonin modulation on pain does not involve a direct
effect on M1, while tDCS does (Reidler et al., 2012; Knotkova
et al., 2013).
In addition, we have shown that melatonin’s effect on pain
is not mediated by descending pain control systems. In fact, in
this study, using the CPM task, the pain score on the NPS0−10
was reduced by more than 30% in all of the treatment groups
including the control group. This is consistent with previous
studies demonstrating an approximated CPM effect of 29%
(Pud et al., 2005, 2009; Niesters et al., 2013). The conditioning
stimulus used in this study (hand placed in water at 0–1◦C
for at least 30 s) was a strong, painful stimulus that depresses
the nociceptive messages elicited from remote localized body
areas. Here, ceiling effects were also possible, i.e., the CPM
responses were at their maximum effect given the intensity of
the conditioning stimulus used. However, other studies have
shown that it is possible to modulate CPM using melatonin, if
used in the long-term (de Zanette et al., 2014), or with tDCS
alone (Reidler et al., 2012). These results, namely the lack of
melatonin-induced M1 modulation and descending inhibitory
pain system involvement, support to some extent the notion
that acute melatonin after-effects may have limited impact on
cortical and spinal systems, thus suggesting that melatonin may
modulate subcortical centers. However, this hypothesis needs
to be confirmed in further trials with other neurophysiological
techniques or functional imaging techniques, such as quantitative
electroencephalography, near-infrared spectroscopy (NIRS) or
functional magnetic resonance imaging (fMRI).
The a-tDCS effect on the corticospinal system is related to
increased MEP amplitude (Table 2), an effect that is consistent
with previous studies that the anodal tDCS over the M1 induced
an enhancement of the corticospinal excitability (Pellicciari et al.,
2013). The tDCS effect on the cortico-subcortical networks is also
supported by recent evidence of a functional coupling increase on
the thalamo-cortical circuits following anodal stimulation over
the motor cortex (Polanía et al., 2012). We speculate that the not
site-limited cortical excitability increase could be determined by
a decrease of the contralateral hemisphere inhibition, mediated,
at least partially, by the anodal tDCS-induced reduction of GABA
concentration (Stagg et al., 2009). Also, the tDCSmight induce an
increased cortical evoked response with a probable concurrent
involvement of the N-Methyl-D-aspartate (NMDA) receptors
(Islam et al., 1995; Nitsche et al., 2003). Thus, these findings
suggest that the modulatory effects produced by a-tDCS were
not limited to the targeted cortical area but also occur at distant
interconnected sites including spinal tract. Given the results, it is
likely that the tDCS does not have a direct excitatory or inhibitory
effect but mostly a modulation role, presumably expressed as to
changes in the excitability of cortical circuits.
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The present findings showed that the use of melatonin alone
or with tDCS did not induce changes in the serum BDNF levels.
Although it is widely distributed in the CNS, the BDNF has been
used as a possible neuroplasticity marker that is modulated by
rTMS (Dall’Agnol et al., 2014), tDCS (Brunoni et al., 2014), or
melatonin treatment (Schwertner et al., 2013; de Zanette et al.,
2014), particularly when assessed in the long-term treatment of
chronic pain. However, in this study, serum BDNFwasmeasured
in healthy subjects and only a short time after one intervention
session. Another possible explanation of the lack of changes
in serum BDNF in the present study is that the intervention
effect was not sufficient to induce a level of neuroplasticity
detectable on serum BDNF. These hypotheses are plausible
considering that BDNF is produced in the CNS and transported
through the blood-brain barrier via saturable systems (Poduslo
and Curran, 1996; Pan et al., 1998; Asmundson et al., 1999).
Although the study demonstrated that the CNS contributes to
70−80% of the circulating BDNF (Rasmussen et al., 2009), this
measure may underestimate its real level in the CNS, since it was
demonstrated that in healthy subjects it can be 14-fold the BDNF
level in the plasma (Yoshimura et al., 2014). These findings
are important for understanding the physiological mechanisms
and the pharmacological and non-pharmacological substrates
of the combined effect of melatonin and active-tDCS on pain.
However, for a better comprehension this effect further studies
are needed in patients with chronic pain, which show amplified
sensory pain.
It is important to emphasize that we chose a cross-
over design as to have a single-subject design, in which the
subjects serve as their own control. This design is sensitive
to individual organism’s differences allowing better assessment
of causal relationship between the independent and dependent
variables (Xeniditis et al., 2001; Dallery et al., 2013). Whereas
it reduces the between subjects comparison, it is an ideal
strategy to validate results because subjects have significant
variability when assessing outcomes related to behavior and
physiological parameters. In addition this design also helps
with controlling between-subject differences in the effects of
stimulation as recent evidence based computational models
suggest that inter individual differences in head anatomy
may affect the distribution of the electric field in the brain
and that a uniform dose of stimulation for all patients may
not be the most efficient procedure (Datta et al., 2012).
Given the costs associated with individual modeling required
to customize the stimulation on an individual basis, our
design controls for this issue as we compare the same
subjects before and after each intervention (Datta et al.,
2012).
Several issues concerning the design of our study must be
address: First, the absence of a group of placebo plus a-tDCS
is a limitation of our study. However, previous studies showed
the effectiveness of a-tDCS in increasing on sensory and pain
thresholds in healthy individuals and pain levels in patients
with chronic pain (Vaseghi et al., 2014). Other possibility to
explain this finding is that s-tDCS potentiates the mechanisms
involved in placebo analgesia as suggested by a recent study
(Dossantos et al., 2014). Second, even though the tDCS is an
efficient technical solutions to conduct blinded studies of both
the patients and experimenters (Gandiga et al., 2006) the efficacy
of patient blinding has been questioned especially be present at
stimulation intensities of 2 mA compared with lower intensities
(O’Connell et al., 2012). However, it is improbable that the
unblinding change the directions of our conclusions, because the
findings did not change when analyzing only subjects that did not
guess the allocation group. Accordingly, as neurophysiological
studies have shown a stimulation shorter than 3 min induce no
significant after–effects (Nitsche and Paulus, 2000). Third, we
included only males subjects, because an enhanced pain response
in females has been attributed to physiological and psychological
variables, including mechanisms of endogenous inhibition, the
capability to endure pain, genetic factors, pain expectation and
personality traits (Keefe et al., 2000; Wiesenfeld-Hallin, 2005).
In this context, the gender may be an important confounding
factor because female are more prone to activation upon negative
emotional responses (i.e., stress, fear, and anxiety) and higher
trait-anxiety is associated with an imbalance between excitatory
and inhibitory descending systems of the corticospinal tract
(Vidor et al., 2014). Another factor to consider is the hormonal
variation throughout the menstrual cycle. Finally, even after the
adjustment for multiple comparisons the effect of melatonin
was significantly on heat pain threshold and the a-tDCS on
MEP (see Table 2). We agree that our study, as the majority
of similar studies has also an exploratory nature and thus it is
possible that our study has increased type I and type II error.
Hence the results of secondary outcomes should be interpreted
as explanatory.
The melatonin effectively reduced pain; however, its
association with a-tDCS did not present an additional
modulatory effect on acute induced pain. Melatonin effects
on induced acute pain did not seem to be mediated by cortical or
brainstem modulation given the lack of results from the cortical
excitability and descending pain control systems. Although the
a-tDCS changed the cortical-spinal excitability assessed by MEP
this effect not changed the CPM. In fact, these findings might
have physiological implications to support an understanding
of the maximum homeostatic physiological control when are
used combined interventions which have common targets to
modulate the painful stimuli.
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